PhaseRx (PZRX) Earns Daily News Impact Score of 0.07
Press coverage about PhaseRx (NASDAQ:PZRX) has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PhaseRx earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.9862721966223 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of PhaseRx (NASDAQ PZRX) traded up 10.552% during trading on Friday, reaching $0.901. 911,449 shares of the company were exchanged. PhaseRx has a one year low of $0.54 and a one year high of $3.30. The firm’s 50 day moving average price is $0.83 and its 200 day moving average price is $0.83. The company has a market capitalization of $10.53 million, a PE ratio of 1.269 and a beta of 6.84.
PhaseRx (NASDAQ:PZRX) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Equities research analysts forecast that PhaseRx will post ($1.46) earnings per share for the current fiscal year.
PhaseRx Company Profile
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Stock Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related stocks with our FREE daily email newsletter.